2026-06-14T03:42:25Zhttps://repisalud.isciii.es/rest/oai/request
oai:repisalud.isciii.es:20.500.12105/51192024-09-27T08:33:59Zcom_20.500.12105_19604com_20.500.12105_2051col_20.500.12105_19605
Repisalud author Bobi, Joaquim author Solanes, Nuria author Fernandez-Jimenez, Rodrigo author Galan-Arriola, Carlos author Dantas, Ana Paula author Fernandez-Friera, Leticia author Galvez-Monton, Carolina author Rigol-Monzo, Elisabet author Aguero, Jaume author Ramirez, Jose author Roque, Merce author Bayes-Genis, Antoni author Sanchez-Gonzalez, Javier author Garcia-Alvarez, Ana author Sabaté, Manel author Roura, Santiago author Ibáñez, Borja author Rigol, Montserrat funder Unión Europea. Fondo Europeo de Desarrollo Regional (FEDER/ERDF) funder Instituto de Salud Carlos III funder Ministerio de Educación y Ciencia (España) funder Fundación Jesús Serra funder Fundación Interhospitalaria de Investigación Cardiovascular funder Medis Medical Imaging funder Ministerio de Economía, Industria y Competitividad (España) funder Fundación ProCNIC funder Fundación La Caixa funder Government of Catalonia (España) funder Fundación La Marató TV3 2017-10-20T10:23:12Z 2017-10-20T10:23:12Z 2017 J Am Heart Assoc. 2017; 6(5):e005771 10.1161/JAHA.117.005771 2047-9980 Journal of the American Heart Association 28468789 http://hdl.handle.net/20.500.12105/5119 Background-Autologous adipose tissue-derived mesenchymal stem cells (ATMSCs) therapy is a promising strategy to improve post-myocardial infarction outcomes. In a porcine model of acute myocardial infarction, we studied the long-term effects and the mechanisms involved in allogeneic ATMSCs administration on myocardial performance. Methods and Results-Thirty-eight pigs underwent 50 minutes of coronary occlusion; the study was completed in 33 pigs. After reperfusion, allogeneic ATMSCs or culture medium (vehicle) were intracoronarily administered. Follow-ups were performed at short (2 days after acute myocardial infarction vehicle-treated, n=10; ATMSCs-treated, n=9) or long term (60 days after acute myocardial infarction vehicle-treated, n=7; ATMSCs-treated, n=7). At short term, infarcted myocardium analysis showed reduced apoptosis in the ATMSCs-treated animals (48.6 +/- 6\% versus 55.9 +/- 5.7\% in vehicle; P=0.017); enhancement of the reparative process with up-regulated vascular endothelial growth factor, granulocyte macrophage colony-stimulating factor, and stromal-derived factor-1 alpha gene expression; and increased M2 macrophages (67.2 +/- 10\% versus 54.7 +/- 10.2\% in vehicle; P=0.016). In long-term groups, increase in myocardial perfusion at the anterior infarct border was observed both on day-7 and day-60 cardiac magnetic resonance studies in ATMSCs-treated animals, compared to vehicle (87.9 +/- 28.7 versus 57.4 +/- 17.7 mL/min per gram at 7 days; P=0.034 and 99 +/- 22.6 versus 43.3 +/- 14.7 22.6 mL/min per gram at 60 days; P=0.0001, respectively). At day 60, higher vascular density was detected at the border zone in the ATMSCs-treated animals (118 +/- 18 versus 92.4 +/- 24.3 vessels/mm(2) in vehicle; P=0.045). Cardiac magnetic resonance-measured left ventricular ejection fraction of left ventricular volumes was not different between groups at any time point. Conclusions-In this porcine acute myocardial infarction model, allogeneic ATMSCs-based therapy was associated with increased cardioprotective and reparative mechanisms and with better cardiac magnetic resonance-measured perfusion. No effect on left ventricular volumes or ejection fraction was observed. eng adipose tissue-derived mesenchymal stem cells allogeneic origin myocardial infarction myocardial perfusion vascular density RANDOMIZED PHASE-1 TRIAL CARDIAC-FUNCTION ISCHEMIC CARDIOMYOPATHY PROMOTE ANGIOGENESIS PROGENITOR CELLS HEART-FAILURE PORCINE MODEL DISEASE THERAPY ISCHEMIA/REPERFUSION Intracoronary Administration of Allogeneic Adipose Tissue-Derived Mesenchymal Stem Cells Improves Myocardial Perfusion But Not Left Ventricle Function, in a Translational Model of Acute Myocardial Infarction journal article URL https://repisalud.isciii.es/bitstreams/e5ec4cc0-0985-4443-821f-afca06c511df/download File MD5 df1784b6f7f20e2404e8930915ee10ba 2882242 application/pdf IntracoronaryAdministrationOfAllogeneic_2017 URL https://repisalud.isciii.es/bitstreams/1739480e-3654-4047-bf8e-fb15d4d094a6/download File MD5 06bb5b7774929bfd6a78b444c2953c83 72377 text/plain IntracoronaryAdministrationOfAllogeneic_2017.txt URL https://repisalud.isciii.es/bitstreams/31fbc2c8-9d91-4c26-9f90-bcb57ed76d08/download File MD5 06bb5b7774929bfd6a78b444c2953c83 72377 text/plain IntracoronaryAdministrationOfAllogeneic_2017.txt